Stock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement

Stock Track04-15

DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical company revealed its board has approved a plan to issue RMB-denominated shares, aiming to raise funds primarily for new drug research and development.

The move represents DualityBio's strategy to establish a dual "H+A" capital platform, with the Hong Kong market providing international capital access and the A-share market offering potentially higher valuations and liquidity. According to market analysis, A-share valuations for biopharmaceutical companies typically command a 30%-60% premium over their H-share counterparts, which could lead to a valuation re-rating for DualityBio.

The company plans to use approximately 85% of the raised funds for new drug R&D, focusing on global development of core products DB-1311 and DB-1310, while the remaining 15% will supplement working capital. This strategic capital move comes as DualityBio advances its position as a global leader in ADC (antibody-drug conjugate) innovation, with multiple pipeline assets approaching key clinical and commercialization milestones.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170833307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170833307","market":"nz","top_or_hot":-1,"title":"Stock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement","media":"Stock Track","content":"<p>DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical company revealed its board has approved a plan to issue RMB-denominated shares, aiming to raise funds primarily for new drug research and development.</p><p>The move represents DualityBio's strategy to establish a dual \"H+A\" capital platform, with the Hong Kong market providing international capital access and the A-share market offering potentially higher valuations and liquidity. According to market analysis, A-share valuations for biopharmaceutical companies typically command a 30%-60% premium over their H-share counterparts, which could lead to a valuation re-rating for DualityBio.</p><p>The company plans to use approximately 85% of the raised funds for new drug R&D, focusing on global development of core products DB-1311 and DB-1310, while the remaining 15% will supplement working capital. This strategic capital move comes as DualityBio advances its position as a global leader in ADC (antibody-drug conjugate) innovation, with multiple pipeline assets approaching key clinical and commercialization milestones.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical company revealed its board has approved a plan to issue RMB-denominated shares, aiming to raise funds primarily for new drug research and development.</p><p>The move represents DualityBio's strategy to establish a dual \"H+A\" capital platform, with the Hong Kong market providing international capital access and the A-share market offering potentially higher valuations and liquidity. According to market analysis, A-share valuations for biopharmaceutical companies typically command a 30%-60% premium over their H-share counterparts, which could lead to a valuation re-rating for DualityBio.</p><p>The company plans to use approximately 85% of the raised funds for new drug R&D, focusing on global development of core products DB-1311 and DB-1310, while the remaining 15% will supplement working capital. This strategic capital move comes as DualityBio advances its position as a global leader in ADC (antibody-drug conjugate) innovation, with multiple pipeline assets approaching key clinical and commercialization milestones.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1170833307","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170833307","pubTimestamp":1776216839,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"个股赛道|DUALITYBIO-B盘中大涨5.02%科创板上市计划公告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical company revealed its board has approved a plan to issue RMB-denominated shares, aiming to raise funds primarily for new drug research and development.The move represents DualityBio's strategy to establish a dual \"H+A\" capital platform, with the Hong Kong market providing international capital access and the A-share market offering potentially higher valuations and liquidity. According to market analysis, A-share valuations for biopharmaceutical companies typically command a 30%-60% premium over their H-share counterparts, which could lead to a valuation re-rating for DualityBio.The company plans to use approximately 85% of the raised funds for new drug R&D, focusing on global development of core products DB-1311 and DB-1310, while the remaining 15% will supplement working capital. This strategic capital move comes as DualityBio advances its position as a global leader in ADC (antibody-drug conjugate) innovation, with multiple pipeline assets approaching key clinical and commercialization milestones.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170833307","isCrawlerRequest":true}